TGFB1 and myelodysplastic syndrome: Luspatercept, an inhibitor of TGF-β signaling, has been recently approved by the FDA for the treatment of transfusion-dependent LR-MDS patients either after failure of erythropoiesis-stimulating agents or at the first line (57).